The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Company handles 20,000+ AI-driven calls and chats daily as it scales agentic AI systems across healthcare workflows
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Subscribe To Our Newsletter & Stay Updated
